Alnara Pharmaceuticals
Alnara Pharmaceuticals develops and commercializes orally-delivered protein therapeutics for the treatment of metabolic diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD191—286m (Dealroom.co estimates Jan 2010.)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
$20.0m | Series A | ||
| $35.0m | Series B | |
$280m | Acquisition | ||
| Total Funding | CAD75.0m | ||
Related Content
Recent News about Alnara Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.